Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | RAD52 | P43351 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | FLT3 | P36888 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5450903 | 0.73 | L3MBTL1 (0.58) | KMT2AL3MBTL1NPC1RAB9APOLB | |
| SCHEMBL5459212 | 0.73 | KMT2A (0.48) | RXFP1KMT2AL3MBTL1RAD52NPC1 | |
| SCHEMBL5453198 | 0.72 | ATM (0.62) | KMT2ARAD52NPC1RAB9APOLB | |
| SCHEMBL5460132 | 0.72 | L3MBTL1 (0.62) | KMT2AL3MBTL1NPC1RAB9APOLB | |
| SCHEMBL5454130 | 0.72 | L3MBTL1 (0.66) | KMT2AL3MBTL1POLBMEN1FLT3 | |
| SCHEMBL5459233 | 0.71 | POLB (0.59) | KMT2AL3MBTL1NPC1RAB9APOLB | |
| SCHEMBL5453354 | 0.70 | PLA2G2A (0.47) | KMT2AL3MBTL1MEN1 | |
| SCHEMBL8270880 | 0.69 | AKR1C2 (0.74) | RXFP1KMT2AAKR1C2MEN1 | |
| Deboxamet SCHEMBL29387753 | 0.69 | AKR1C2 (0.74) | RXFP1KMT2AAKR1C2MEN1 | |
| Deboxamet SCHEMBL186946 | 0.69 | AKR1C2 (0.74) | RXFP1KMT2AAKR1C2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | RXFP1 4595/4885KMT2A 4785/4885L3MBTL1 2796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.